Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.

被引：0
|
作者：
Sobrero, A.
Ackland, S.
Carrion, R. P.
Chiara, S.
Clarke, S.
Giron, C. G.
Langer, B.
Zurlo, A.
Young, S.
机构：
[1] Azienda Osped San Martino Genova, I-16132 Genoa, Italy
[2] Newcastle Mater Misericordiae Hosp, Waratah, Australia
[3] Ctr Oncol MD Anderson Int Espana, Madrid, Spain
[4] Ist Nazl Ric Canc, Genoa, Italy
[5] Concord Repatriat Gen Hosp, Concord, Australia
[6] Hosp Gen Yague, Burgos, Spain
[7] NE Ontario Reg Canc Ctr, Sudbury, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3544
引用
收藏
页码：157S / 157S
页数：1
相关论文
共 50 条
  • [1] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    [J]. VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [3] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [4] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [5] MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN
    Holmberg, C.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    Gyldmark, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [6] First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial
    Sobrero, A.
    Ackland, S.
    Perez Carrion, R.
    Chiara, S.
    Clarke, S.
    Garcia Giron, C.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 31 - 31
  • [7] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    P García-Alfonso
    A J Muñoz-Martin
    S Alvarez-Suarez
    Y Jerez-Gilarranz
    M Riesco-Martinez
    P Khosravi
    M Martin
    [J]. British Journal of Cancer, 2010, 103 : 1524 - 1528
  • [8] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    Garcia-Alfonso, P.
    Munoz-Martin, A. J.
    Alvarez-Suarez, S.
    Jerez-Gilarranz, Y.
    Riesco-Martinez, M.
    Khosravi, P.
    Martin, M.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1524 - 1528
  • [9] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [10] A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC:: AVIRI
    Sobrero, A.
    Young, S.
    Balcewicz, M.
    Chiara, S.
    Perez-Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII18 - VII19
12345